HMGA2 and central nervous system cancer: Moreover, the samples of our tumor cohort with grade I‐IV gliomas and the GBMs from the TCGA database with a higher HMGA2 level had shorter DFS and OS, and both multivariate and univariate analyses using our data identified HMGA2 as an independent predictor of glioma patient survival, indicating that HMGA2 is a specific biomarker for prognosis‐based glioma subclassification.